[HTML][HTML] Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
L Galasso, L Cerrito, V Maccauro, F Termite… - International Journal of …, 2024 - mdpi.com
Hepatocellular carcinoma (HCC) is the most frequent among primary liver tumors (90%) and
one of the main causes of cancer-related death. It develops usually in a chronically inflamed …
one of the main causes of cancer-related death. It develops usually in a chronically inflamed …
Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma
SK Shin, S Oh, SK Chun, MJ Ahn… - Journal of …, 2024 - Wiley Online Library
Natural killer (NK) cells are one of the key members of innate immunity that predominantly
reside in the liver, potentiating immune responses against viral infections or malignant …
reside in the liver, potentiating immune responses against viral infections or malignant …
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
J Hong, JW Eun, GO Baek, JY Cheong, S Park… - Clinical and Molecular …, 2024 - e-cmh.org
Methods We generated whole-transcriptome sequencing (WTS) and targeted proteome data
from buffy coat and plasma samples from HCC patients. By integrating etiological …
from buffy coat and plasma samples from HCC patients. By integrating etiological …
An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness
H Peng, K Feng, W Jia, Y Li, Q Lv, Y Zhang - Apoptosis, 2024 - Springer
The cytosolic sulfotransferases (SULTs) are phase II conjugating enzymes, which are widely
expressed in the liver and mainly mediate the sulfation of numerous xenobiotics and …
expressed in the liver and mainly mediate the sulfation of numerous xenobiotics and …
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma
YR Kim, SW Chung, MJ Kim, WM Choi… - Journal of …, 2024 - Taylor & Francis
Introduction We aimed to evaluate the generalizability of retrospective single-center cohort
studies on prognosis of hepatocellular carcinoma (HCC) by comparing overall survival (OS) …
studies on prognosis of hepatocellular carcinoma (HCC) by comparing overall survival (OS) …
[HTML][HTML] Advances in chemotherapy-resistant hepatocellular carcinoma
S Liu, Q Li, Y Li, J Sheng - Frontiers in Medicine, 2023 - frontiersin.org
Primary liver cancer, including hepatocellular carcinoma and cholangiocarcinoma, has a
poor prognosis. According to the American Cancer Society statistics, the 5-year survival rate …
poor prognosis. According to the American Cancer Society statistics, the 5-year survival rate …
[HTML][HTML] Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
JE Han, HJ Cho - Clinical and Molecular Hepatology, 2024 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and a
leading cause of cancer-related mortality worldwide. Many cases of HCC are diagnosed at …
leading cause of cancer-related mortality worldwide. Many cases of HCC are diagnosed at …
[HTML][HTML] Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
HJ Lee, JS Lee, H So, JK Yoon, JY Choi, HW Lee… - Yonsei Medical …, 2024 - ymj.or.kr
Purpose Nivolumab and regorafenib are second-line therapies for patients with advanced
hepatocellular carcinoma (HCC). We aimed to compare the effectiveness of nivolumab and …
hepatocellular carcinoma (HCC). We aimed to compare the effectiveness of nivolumab and …
Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
Methods This study analyzed 248 consecutive patients with HCC and EHM (median age
58.5 years, 83.5% male, and 88.7% Child-Pugh A) who received TACE or systemic therapy …
58.5 years, 83.5% male, and 88.7% Child-Pugh A) who received TACE or systemic therapy …
[HTML][HTML] Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
혜연전 - The Korean Journal of Gastroenterology - synapse.koreamed.org
최근 5 년 동안 진행성 간암에서 PD-1/PD-L1 경로를 표적으로 하는 면역관문억제제 (Immune
check point inhibitor, ICI) 가 새로운 치료 약제로서 대두되었다. 하지만 현재까지 진행성 …
check point inhibitor, ICI) 가 새로운 치료 약제로서 대두되었다. 하지만 현재까지 진행성 …